Cytoreduction of @entity706 and mobilization of blood hematopoietic progenitor cells with high doses of XXXX and @entity2879 plus filgrastim.

@entity1 @entity137 @entity3136 @entity1261 @entity706 @entity5 @entity786 @entity2879 @entity1582 @entity2280 @entity1893 @entity8057
We evaluated the efficiency of high doses of @entity786 (6 g/m2) and @entity2879 (2 g/m2) plus filgrastim (granulocyte colony-stimulating factor; @entity1261 ) to mobilize autologous hematopoietic progenitor cells in @entity1 with @entity1893 , @entity1582 , and @entity8057 . We also evaluated the safety of this regimen and the engraftment kinetics after myeloablative chemotherapy. Seventy-nine @entity1 with high-risk or relapsed/primary @entity1893 , @entity1582 , or @entity8057 were treated. The mobilizing regimen was as follows: @entity786 600 mg/m2 twice daily for 10 doses, @entity2879 200 mg/m2 twice daily for 10 doses (continuous; n=57) or 2 g/m2 over 10 hours on day 5 of @entity2879 (bolus; n=22), and @entity1261 5 microg/kg/d beginning day 14. Fifty-nine percent of @entity1 achieved the primary end point (a @entity2280 cell dose of 5 million per kilogram with a single leukapheresis). More bolus @entity2879 @entity1 achieved the primary end point (86%) compared with continuous @entity2879 @entity1 (47%; P<.0001). The @entity2280 cell dose collected was greater in bolus @entity2879 @entity1 (44 million per kilogram) than in continuous @entity2879 @entity1 (10.9 million per kilogram; P<.0001). @entity1 took 3 weeks to recover >500/microL neutrophils and >20000/microL platelets after @entity786 and @entity2879 . The overall response rate was 69% for @entity1893 @entity1 and 71% for @entity1582 / @entity8057 @entity1 . The treatment-related mortality was 2.5%. Sixteen percent of surviving @entity1 experienced grade>or=3 nonhematologic @entity137 . @entity1 receiving bolus @entity2879 had significantly less grade>or=2 @entity3136 , less use of total parenteral nutrition, and less need for red blood cell and platelet transfusions. Sixty-four @entity1 (81%) underwent autologous hematopoietic progenitor cell transplantation, with prompt engraftment. Four @entity1 (5%) did not undergo autologous hematopoietic progenitor cell transplantation because of @entity137 from high-dose @entity786 and @entity2879 . We conclude that high doses of @entity786 and @entity2879 combined with @entity1261 are an efficient and safe mobilizing regimen for the collection of hematopoietic progenitor cells during aggressive cytoreduction of @entity5 burden in @entity1 with @entity706 .
